scholarly journals Using velocity-pressure loops in the operating room: a new approach of arterial mechanics for cardiac afterload monitoring under general anesthesia

2019 ◽  
Vol 317 (6) ◽  
pp. H1354-H1362 ◽  
Author(s):  
A. Hong ◽  
J. Joachim ◽  
C. Buxin ◽  
C. Levé ◽  
A. Le Gall ◽  
...  

Cardiac afterload is usually assessed in the ascending aorta and can be defined by the association of peripheral vascular resistance (PVR), total arterial compliance (Ctot), and aortic wave reflection (WR). We recently proposed the global afterload angle (GALA) and β-angle derived from the aortic velocity-pressure (VP) loop as continuous cardiac afterload monitoring in the descending thoracic aorta. The aim of this study was to 1) describe the arterial mechanic properties by studying the velocity-pressure relations according to cardiovascular risk (low-risk and high-risk patients) in the ascending and descending thoracic aorta and 2) analyze the association between the VP loop (GALA and β-angle) and cardiac afterload parameters (PVR, Ctot, and WR). PVR, Ctot, WR, and VP loop parameters were measured in the ascending and descending thoracic aorta in 50 anesthetized patients. At each aortic level, the mean arterial pressure (MAP), cardiac output (CO), and PVR were similar between low-risk and high-risk patients. In contrast, Ctot, WR, GALA, and β-angle were strongly influenced by cardiovascular risk factors regardless of the site of measurement along the aorta. The GALA angle was inversely related to aortic compliance, and the β-angle reflected the magnitude of wave reflection in both the ascending and descending aortas ( P < 0.001). Under general anesthesia, the VP loop can provide new visual insights into arterial mechanical properties compared with the traditional MAP and CO for the assessment of cardiac afterload. Further studies are necessary to demonstrate the clinical utility of the VP loop in the operating room. NEW & NOTEWORTHY Our team recently proposed the global afterload angle (GALA) and β-angle derived from the aortic velocity-pressure (VP) loop as continuous cardiac afterload monitoring in the descending thoracic aorta under general anesthesia. However, the evaluation of cardiac afterload at this location is unusual. The present study shows that VP loop parameters can describe the components of cardiac afterload both in the ascending and descending thoracic aorta in the operating room. Aging and cardiovascular risk factors strongly influence VP loop parameters. The VP loop could provide continuous visual additional information on the arterial system than the traditional mean arterial pressure and cardiac output during the general anesthesia.

2012 ◽  
Vol 2 (1) ◽  
pp. 5-13
Author(s):  
Hajera Mahtab ◽  
Razia Sultana Mahmud ◽  
Kukkum Pervin ◽  
Md Javed Sobhan

Background and aim: This study was to evaluate atorvastatin in the management of hypercholesterolemia of cardiovascular risk patients as well as the implication of National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines in Bangladesh.Methods: A total 1685 patients aged 28 years or older who had evidence of hypercholesterolemia with or without Coronary Heart Diseases (CHD) and cardiovascular risk factors were assigned to receive atorvastatin for 2 months. The change of fasting LDL at baseline visit and after 2 months of the statin treatment was measured.Results: One thousand six hundred (95%) patients out of 1685 who were assigned to receive atorvastatin with TLC were found significant mean reduction (26.1%?) in their LDL levels from baseline visit. Triglycerides and total cholesterols were also reduced (16.6% ? and 21.6% ? respectively) wheras high-density lipoprotein was increased (16.5% ?) significantly. LDL of 23% patients was decreased more than 30 mg/dl after 2 months of atorvastatin treatment. Fifty nine percent of the patients reached the treatment goal of reducing LDL > 20 mg/dl.Conclusion: Atorvastatin would achieve a good effective control in the management of hypercholesterolemic patients with or without CHD and risk factors following the guidelines of US NCEP ATP III. DOI: http://dx.doi.org/10.3329/birdem.v2i1.12354 Birdem Med J 2012; 2(1) 5-13


2014 ◽  
pp. 254-261 ◽  
Author(s):  
Katarzyna Mizia-Stec ◽  
Joanna Wieczorek ◽  
Michał Orszulak ◽  
Magdalena Mizia ◽  
Klaudia Gieszczyk-Strózik ◽  
...  

2015 ◽  
Vol 62 (3) ◽  
pp. 832-833
Author(s):  
Jeffrey Jim ◽  
Luis A. Sanchez ◽  
Andrea Kahlberg ◽  
Germano Melissano ◽  
Feiyi Jia ◽  
...  

1995 ◽  
Vol 8 (3) ◽  
pp. 369
Author(s):  
David H Montgomery ◽  
Harland Austin ◽  
John J Ververis ◽  
Stephen Frohwein ◽  
Randolph P Martin ◽  
...  

Medicina ◽  
2020 ◽  
Vol 56 (3) ◽  
pp. 134
Author(s):  
Gediminas Urbonas ◽  
Lina Vencevičienė ◽  
Leonas Valius ◽  
Ieva Krivickienė ◽  
Linas Petrauskas ◽  
...  

Background and Objectives: Cardiovascular disease (CVD) prevention guidelines define targets for lifestyle and risk factors for patients at high risk of developing CVD. We assessed the control of these factors, as well as CVD risk perception in patients enrolled into the primary care arm of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE V) survey in Lithuania. Materials and Methods: Data were collected as the part of the EUROASPIRE V survey, a multicenter, prospective, cross-sectional observational study. Adults without a documented CVD who had been prescribed antihypertensive medicines and/or lipid-lowering medicines and/or treatment for diabetes (diet and/oral antidiabetic medicines and/or insulin) were eligible for the survey. Data were collected through the review of medical records, patients’ interview, physical examination and laboratory tests. Results: A total of 201 patients were enrolled. Very few patients reached targets for low-density lipoprotein cholesterol (LDL-C) (4.5%), waist circumference (17.4%) and body mass index (15.4%). Only 31% of very high CVD risk patients and 52% of high-risk patients used statins. Blood pressure target was achieved by 115 (57.2%) patients. Only 21.7% of patients at very high actual CVD risk and 27% patients at high risk correctly estimated their risk. Of patients at moderate actual CVD risk, 37.5% patients accurately self-assessed the risk. About 60%–80% of patients reported efforts to reduce the intake of sugar, salt or alcohol; more than 70% of patients were current nonsmokers. Only a third of patients reported weight reduction efforts (33.3%) or regular physical activity (27.4%). Conclusions: The control of cardiovascular risk factors in a selected group of primary prevention patients was unsatisfactory, especially in terms of LDL-C level and body weight parameters. Many patients did not accurately perceive their own risk of developing CVD.


Blood ◽  
2010 ◽  
Vol 116 (8) ◽  
pp. 1205-1210 ◽  
Author(s):  
Alberto Alvarez-Larrán ◽  
Francisco Cervantes ◽  
Arturo Pereira ◽  
Eduardo Arellano-Rodrigo ◽  
Virginia Pérez-Andreu ◽  
...  

Abstract The effectiveness of antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia (ET) is not proven. In this study, the incidence rates of arterial and venous thrombosis were retrospectively analyzed in 300 low-risk patients with ET treated with antiplatelet drugs as monotherapy (n = 198) or followed with careful observation (n = 102). Follow-up was 802 and 848 person-years for antiplatelet therapy and observation, respectively. Rates of thrombotic events were 21.2 and 17.7 per 1000 person-years for antiplatelet therapy and observation, respectively (P = .6). JAK2 V617F–positive patients not receiving antiplatelet medication showed an increased risk of venous thrombosis (incidence rate ratio [IRR]: 4.0; 95% CI: 1.2-12.9; P = .02). Patients with cardiovascular risk factors had increased rates of arterial thrombosis while on observation (IRR: 2.5; 95% CI: 1.02-6.1; P = .047). An increased risk of major bleeding was observed in patients with platelet count greater than 1000 × 109/L under antiplatelet therapy (IRR: 5.4; 95% CI: 1.7-17.2; P = .004). In conclusion, antiplatelet therapy reduces the incidence of venous thrombosis in patients with JAK2-positive ET and the rate of arterial thrombosis in patients with associated cardiovascular risk factors. In the remaining low-risk patients, this therapy is not effective as primary prophylaxis of thrombosis, and observation may be an adequate option.


Sign in / Sign up

Export Citation Format

Share Document